Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1998-3-3
|
pubmed:abstractText |
An inverse relationship between BCL-2 expression and cell cycle transition has been suggested by recent studies in murine models. To investigate the clinical relevance of these laboratory studies, a group of 116 paraffin-embedded non-Hodgkin's lymphoma (NHL) biopsy specimens (Working Formulation Groups D-H, and J) from a cooperative group study of cellular DNA content were analyzed for the 14;18 translocation using polymerase chain reaction (PCR)-based methods and, if sufficient tissue remained, for BCL-2 and BAX expression by immunohistochemistry. The results of these studies were then compared with the results of the previously performed flow cytometric analysis of ploidy and proliferative activity (S-phase-fraction). BCL-2 expression was inversely associated with proliferative activity (P = .001; n = 41), but there was no association between staining for Bax and %S-phase. Ploidy was not associated with either BCL-2 or BAX expression. The t(14;18) was detected in 21 of the 54 cases in which PCR-amplifiable DNA was recovered; 20 of these occurred at the major breakpoint region and 1 at the minor breakpoint region. High levels of BCL-2 or BAX expression occurred independently of t(14;18). There was no association between t(14;18) and either ploidy or proliferative activity. The inverse relationship between BCL-2 expression and proliferative activity in the intermediate- and high-grade NHLs is consistent with recent studies suggesting that Bcl-2 both retards entry into the cell cycle and inhibits apoptosis.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:AndersenJJ,
pubmed-author:BauerK DKD,
pubmed-author:DomerPP,
pubmed-author:FisherR IRI,
pubmed-author:GordonL ILI,
pubmed-author:JeffriesDD,
pubmed-author:JiangSS,
pubmed-author:KrajewskiSS,
pubmed-author:OkenM MMM,
pubmed-author:ReedJ CJC,
pubmed-author:VariakojisDD,
pubmed-author:WiltonDD
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
91
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1391-8
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:9454770-Cell Division,
pubmed-meshheading:9454770-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:9454770-Humans,
pubmed-meshheading:9454770-Immunohistochemistry,
pubmed-meshheading:9454770-Lymphoma, Non-Hodgkin,
pubmed-meshheading:9454770-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:9454770-S Phase
|
pubmed:year |
1998
|
pubmed:articleTitle |
BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.
|
pubmed:affiliation |
Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL 60611, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase III
|